SavedAdd your journal

Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2011 / Sayı: 1

Optical Coherence Tomography In Neuro-Ophthalmological Diseases

Nöro-Oftalmolojik Hastalıklarda Optik Koherens Tomografisi

Abdulbaki MUDUN
Pages
5–9
Publication Date
2011-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

OCT’s wide use in evaluating the optic nerve and the visual system has revolutionized our assessment, management, research, and understanding of neuro-ophthalmic diseases

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Optical coherence tomography OCT provides clinicians with the ability to quantify the thickness of the retinal nerve fiber layer RNFL , which is useful in managing diseases of the optic nerve.
📊
Key Findings & Data:OCT’s advancement refined its ability to image the retinal layers with incredible sensitivity by increasing scanner speed.
💡
Conclusion & Impact:OCT’s wide use in evaluating the optic nerve and the visual system has revolutionized our assessment, management, research, and understanding of neuro-ophthalmic diseases
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:neurodegenerative diseases · optical coherence tomography · optical neuropathy

Abstract

Optical coherence tomography OCT provides clinicians with the ability to quantify the thickness of the retinal nerve fiber layer RNFL , which is useful in managing diseases of the optic nerve. OCT’s advancement refined its ability to image the retinal layers with incredible sensitivity by increasing scanner speed. OCT has been studied in several neuro-ophthalmic conditions, including anterior ischemic optic neuropathy, other toxic and inflamatuar optic neuropathies, multiple sclerosis, neuromyelitis optica, pseudotumor cerebri, migraine,optic nerve head drusen, compressive optic neuropathy, Leber’s hereditary optic neuropathy LHON , Alzheimer’s disease and Friedrich’s disease. The purpose of this review is to coalesce the current literature on the use of OCT in neuro-ophthalmology to enhance its use in clinical practice. OCT’s wide use in evaluating the optic nerve and the visual system has revolutionized our assessment, management, research, and understanding of neuro-ophthalmic diseases

Özet

Optik Koherens Tomografisi OKT klinisyenlere optik sinir hastalıklarına yaklaşımda önemli bilgiler veren retina sinir lifi tabakası RSLT kalınlığını kantitatif olarak ölçme olanağı tanır. OKT cihazları artan tarama hızları sonucu gelişerek retina katlarının görüntülemesinde olağanüstü bir ayrıntıya ve hassasiyete ulaşılmıştır. OKT günümüzde çeşitli nöro-oftalmik durumlarda kullanılmaya başlanmıştır. Bunların arasında anterior iskemik optik nöropati AİON , toksik ve inflamatuar diğer optik nöropatiler, multiple sklerozis, nöromyelitis optika, psödotumor serebri, migren, optic sinir başı druseni, Leber’in herediter optik nöropatisi LHON , Alzheimer hastalığı ve Friedrich hastalığı yer almaktadır. Bu derlemenin amacı nöro-oftalmolojik hastalıklarda OKT kullanımı ile ilgili varolan yayınların gözden geçirilmesi ve klinik uygulamada kullanımını artırmaktır. OKT’nin optik sinir ve görme sistemi hastalıklarının değerlendirilmesinde yaygın kullanımı, nöro-oftalmolojik hastalıklardaki yargılarımızı, yaklaşımımızı, araştırmalarımızı ve anlayışımızı kökten değiştirmektedir

🔖

Cite This Article

MUDUN, A. (2011). Optical Coherence Tomography In Neuro-Ophthalmological Diseases. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Sayı: 1, 5–9. https://ajindex.com/articles/163280

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Frisen L, Hoyt WF. Insidious atrophy of retinal nerve fi bers in multiple sclerosis. Funduscopic identifi cation in patients with and without visual complaints. Arch Ophthalmol 1974; 92: 91–97.
  2. Elbol P, Work K. Retinal nerve fi ber layer in multiple sclerosis. Acta Ophthalmol (Copenh) 1990; 68: 481–486.
  3. Honrubia F, Calonge B. Evaluation of the nerve fi ber layer and peripapillary atrophy in ocular hypertension. Int Ophthalmol 1989; 13: 57–62.
  4. Quigley HA, Addicks EM. Quantitative studies of retinal nerve fi ber layer defects. Arch Ophthalmol 1982; 100: 807–814. Leigh RJ and Wolinsky JS. Keeping eye on MS. Neurology 2001; 57:751-752.
  5. Traboulsee A, Dehmeshki J, Peters KR, Griffi n CM, Brex PA, Silver N, Ciccarrelli O, Chard DT, Barker GJ, Thompson AJ, Miller DH. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 2003; 9:566-573.
  6. Frohman EM, Zhang H, Kramer PD, Fleckenstein J, Hawker K, Racke MK, Frohman TC. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology 2001; 57:762-768.
  7. Frohman EM, Frohman TC, O’Suilleabhain P, Zhang H, Hawker K, Racke MK, Frawley W, Phillips JT, Kramer PD. Quantitative oculographic characterization of internuclear ophthalmoparesis in multiple sclerosis:the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry 2002; 73:51-55.
  8. Fox RJ, McColl RW, Lee JC, Frohman T, Sakaie K, Frohman E. A preliminary validation study of diff usion tensor imaging as a measure of functional brain injury. Arch Neurol 2008; 65:1179-1184.
  9. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sİrensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group. Eff ect of early interferon treatment on conversion to defi nite multiple sclerosis:a randomised study. Lancet 2001; 357:1576-1582.
  10. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a fi rst demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
  11. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically defi nite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249.
  12. Kinkel RP, Kollman C, O’Co